About
BSF Enterprise
Mission Statement
To create a portfolio of innovative subsidiary companies developing and commercialising cell-based tissue engineering solutions to deliver sustainable outcomes across a variety of sectors. The Company’s core technology platform in industrial tissue engineering allows the manufacture at scale of lab-grown alternatives to animal and human tissues.
Ambition Statement
The Company’s technologies have multiple applications across consumer and medical markets including lab-grown leather, cultivated meat, human corneas and in vitro animal models. We aim to be world leaders in the supply of technologies underpinning advanced biomaterials
The Innovation of Tissue Engineering
The function of a tissue is inextricably linked to its form. The shape or form of a tissue is a consequence of its component parts and the nano-scale arrangement of these. Cells have developed processes over billions of years that facilitate production and arrangement of molecules that combine to form a functional tissue. The resulting characteristics of these tissues (strength, feel, taste etc) far exceed anything that can be man-made. Despite this most approaches to tissue engineering have been based upon the use of man-made materials, which without the benefit of billions of years of development ultimately fail. BSF have embraced the innate ability of cells to produce functional tissues and based upon the work of Professor Connon have developed a tissue engineering platform that produces world class tannable skin and cultivated meat. Moreover the rational design of these lab-grown tissues has led to exciting opportunities to improve upon animal made tissues!
Leadership Team
Min Yang - Chair [BoD]
Min Yang, the Chair of BSF Enterprise and a member of the Board of Directors, possesses a wealth of experience spanning over 30 years of in international investment. Min’s expertise lies in the identification, acceleration and realisation of investments across a range of industries including property, resources, technology and finance.
Geoff Baker - Director [BoD]
Geoff Baker, the Director of BSF Enterprise and a member of the Board of Directors, is a qualified lawyer in Australia and Hong Kong. He holds a commerce degree, law degree and a Master of Business Administration. Geoff has practiced extensively for 30 years as a lawyer in Australia, Japan, across Asia and China.
Dr. Che Connon - MD [BoD]
Dr. Che Connon, the Managing Director of BSF Enterprise and a member of the Board of Directors, has over 20 years of experience in extracellular matrix biology. He is currently a Professor of Tissue Engineering at Newcastle University. Dr. Connon has successfully spun out 3 biotech companies.
Dennis Ow - NED [BoD]
Dennis Ow, the Non-Executive Director of BSF Enterprise and a member of the Board of Directors, was a business development and corporate finance executive at various investment banks in Asia. Dennis served as the former Asia Pacific Senior Business Manager for the London Stock Exchange.
Ricardo Gouveia - CSO
Ricardo is a scientist with expertise in Biochemistry, Biotechnology and Bioengineering. With almost 20 years of research experience in stem cell biology and tissue biofabrication, a considerable publication record, and recipient of several accolades, his work represents the foundation of many of 3DBT’s proprietary technologies. As an entrepreneur, he is interested in building strategic R&D partnerships to accelerate the commercialisation of new healthcare, food, and biotech products and processes.
Graham Duncan - CFO
Graham Duncan, the Chief Financial Officer of BSF Enterprise, is a Chartered Accountant with over 20 years of capital markets experience. He holds a Corporate Finance Diploma issued by the ICAEW and has specialised in advising UK-listed companies.